Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis

• Published in: Nanomedicine (London, England) Vol. 14; no. 6; pp. 707 - 726
• Main Authors: Andreu, Vanesa, Larrea, Ane, Rodriguez-Fernandez, Pablo, Alfaro, Salvador, Gracia, Begoña, Lucía, Ainhoa, Usón, Laura, Gomez, Andromeda-Celeste, Mendoza, Gracia, Lacoma, Alicia, Dominguez, Jose, Prat, Cristina, Sebastian, Victor, Ainsa, José Antonio, Arruebo, Manuel
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.03.2019
• Subjects: Acids; Antibiotics; Antimicrobial agents; Clinical medicine; Disease; Drugs; Medical equipment; Nanomaterials; Nanoparticles; Product differentiation; Product life cycle; RNA polymerase; Tuberculosis; rifampicin; PLGA; enteric coating; gastroresistant; eudragit; oral delivery; tuberculosis; TEER; microparticles
• ISSN: 1743-5889; 1748-6963
• DOI: 10.2217/nnm-2018-0258

Aim: Production of Matryoshka-type gastroresistant microparticles containing antibiotic-loaded poly lactic-co-glycolic acid (PLGA) nanoparticles (NP) against Mycobacterium tuberculosis. Materials & methods: The emulsification and evaporation methods were followed for the synthesis of PLGA–NPs and methacrylic acid-ethyl acrylate-based coatings to protect rifampicin from degradation under simulated gastric conditions. Results & conclusion: The inner antibiotic-loaded NPs here reported can be released under simulated intestinal conditions whereas their coating protects them from degradation under simulated gastric conditions. The encapsulation does not hinder the antituberculosis action of the encapsulated antibiotic rifampicin. A sustained antibiotic release could be obtained when using the drug-loaded encapsulated NPs. Compared with the administration of the free drug, a more effective elimination of M. tuberculosis was observed when applying the NPs against infected macrophages. The antibiotic-loaded PLGA–NPs were also able to cross an in vitro model of intestinal barrier.